Aeglea Bio Therapeutics Inc KOL Webinar on Classical Homocystinuria and Pegtarviliase Call Transcript
Good morning, and welcome to the Aeglea KOL webinar. (Operator Instructions) Please note this event is being recorded, and a replay will be made available for replay on the Aeglea BioTherapeutics website following the conclusion of today's event.
I would now like to turn the call over to Jonathan Alspaugh, Chief Financial Officer and our first speaker. Please go ahead, Jonathan.
Thank you, Sarah, and thank you all for joining us this morning for a webinar on homocystinuria.
Before we begin, please note that this webinar may include forward-looking statements under the Private Securities Litigation Reform Act. Actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to materially differ includes, but is not limited to the types of statements identified as forward-looking in our periodic reports filed with the SEC and available on our website.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |